Skip To Main Content
Angelo Pirozzi on Muck Rack

Angelo Pirozzi

As seen in: Nature, MDPI, Taylor & Francis Online, Dove Medical Press, touchONCOLOGY
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Angelo Pirozzi’s profile

Articles by Angelo Pirozzi

Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis

|
By Binbin Zheng-Lin, Taro Shibuki, Heidi E. Kosiorek, Oluseyi Abidoye, Cody Eslinger, Yasuyuki Kawamoto, Ryne C. Ramaker, Shinji Itoh, Tadayoshi Hashimoto, Takao Fujisawa, Mitsuho Imai, Angelo Pirozzi, Celine Hoyek, Mohamad B. Sonbol, Christina Wu, Nguyen Tran, Hani M Babiker, Lewis Roberts, Ashley Moyer, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Makoto Ueno, Chigusa Morizane, Daniel Ahn, Mitesh J. Borad, John Strickler, Masafumi Ikeda, Tanios S Bekaii-Saab, Madhuri Gottam
| Nature Verified
Abstract The prognosis of advanced biliary tract cancer remains poor despite up to 40% of tumors harboring actionable molecular alterations. This international collaborative study from Mayo Clinic, Duke Cancer Institute, National Cancer Center East (Japan), and the SCRUM-Japan GOZILA/MONSTAR-SCREEN projects evaluated clinical outcomes in 1049 patients with advanced BTC based on tumor molecular profiling and matched treatment selection.
Open in Who Shared Issue with article?

Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)

|
By Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Oluseyi Abidoye
| Taylor & Francis Online
ABSTRACT Introduction Futibatinib is a small, potent, covalent, irreversible fibroblast growth factor receptor (FGFR) 1–4 inhibitor that has been added as a new standard of care for previously treated unresectable and/or advanced FGFR2 fusion/rearrangement-positive BTC. FGFR2 fusions/rearrangements play a key role in BTC survival, proliferation, invasion, and development of distant metastasis. The inhibition of this pathway is an important target in the treatment of BTC.
Open in Who Shared Issue with article?

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

|
By Angelo Pirozzi, Jeremy Jones, Lorenza Rimassa, Celine Hoyek
| touchONCOLOGY Verified
Overview Kirsten rat sarcoma virus (KRAS) gene mutations are amongst the most prevalent oncogenic mutations in gastrointestinal tumours. Attempts at targeting the KRAS protein have been unsuccessful for decades, mainly due to its challenging architecture that lacks small-molecule-binding sites.
Open in Who Shared Issue with article?

Advanced hepatocellular carcinoma and treatment

|
By Valentina Zanuso, Angelo Pirozzi, Rita Balsano, Tiziana Pressiani
| Dove Medical Press
Back to Journals » Journal of Hepatocellular Carcinoma » Volume 10 Authors Zanuso V , Pirozzi A , Balsano R, Pressiani T , Rimassa L Received 13 June 2023 Accepted for publication 20 September 2023 Published 2 October 2023 Volume 2023:10 Pages 1689—1708 DOI https://doi.org/10.2147/JHC.S347932 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Ahmed Omar Kaseb Valentina Zanuso,1,2 Angelo Pirozzi,1,2 Rita Balsano,2...
Open in Who Shared Issue with article?

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

|
By Rita Balsano, Valentina Zanuso, Angelo Pirozzi, Lorenza Rimassa
| MDPI
3. Discussion As outlined in previous chapters, the considerable efforts to test the efficacy of ICIs in PDAC have yielded disappointing results. Several possible causes for this failure have been identified.
Open in Who Shared Issue with article?
Show More